In this weeks’ video, Dr. Durie discusses what effect a new treatment can have on your myeloma protein levels, and when it can be time to consider changing your treatment regimen with your doctor.

BOTTOM LINE:
Venetoclax will move forward as a “targeted” precision medicine approach for patients with the t(11;14) abnormality.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

 

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie founded and now serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Previous Post
If the myeloma protein levels stay the same (or only drops slightly) with one cycle of treatment, should you switch to a different therapy?
Next Post
What is GSK 2857916, also known as belantamab mafodotin?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt out, click for more information.